Monash University, Melbourne, Australia. ian.meredith@myheart.id.au
Minerva cardioangiologica 2012 FebDespite the benefits of first generation drug eluting stents (DES), concerns have been raised over their long term safety in particular the risk of stent thrombosis. As a result, the current generation and novel DES have been developed, the latter includes DES with biocompatible and biodegradable polymers, polymer free DES and completely bioresorbable stent platforms. Many of these stents are currently under evaluation in clinical trials, and early results are promising. This paper reviews the progress thus far in DES technology and aims to highlight the impact of recent DES innovations on clinical efficacy and safety.
B S Ko, I T Meredith. New DES: a new step forward? Minerva cardioangiologica. 2012 Feb;60(1):41-56
PMID: 22322573
View Full Text